HCP Live

Genentech enrolling patients for Lucentis clinical trial

Apr 24, 2004

Genentech, South San Francisco, CA, announced that the biotechnologycompany is enrolling patients into a Phase III clinical trial for its age-relatedmacular degeneration (AMD) drug Lucentis (ranibizumab, rhuFab V2).

Related Videos

Related Content

Ocuphire Pharma’s ZETA-1 phase 2 trial of diabetic retinopathy candidate offers mixed results

January 26th 2023

Commercial real estate and your practice, part two with Colin Carr

UT Southwestern ophthalmologist shares techniques for cataract surgery complications

January 26th 2023

Tips, tricks, what to dos and what not to dos on how you can save money as a healthcare provider on your commercial real estate (Part 1)

ARVO announces recipients of 2023 Pfizer Ophthalmics Carl Camras Translational Research Award

January 26th 2023

Expanding gene therapy for Usher Syndrome Type 2A

January 25th 2023

Ocuphire Pharma’s ZETA-1 phase 2 trial of diabetic retinopathy candidate offers mixed results

January 26th 2023

Commercial real estate and your practice, part two with Colin Carr

UT Southwestern ophthalmologist shares techniques for cataract surgery complications

January 26th 2023

Tips, tricks, what to dos and what not to dos on how you can save money as a healthcare provider on your commercial real estate (Part 1)

ARVO announces recipients of 2023 Pfizer Ophthalmics Carl Camras Translational Research Award

January 26th 2023

Expanding gene therapy for Usher Syndrome Type 2A

January 25th 2023

Ocuphire Pharma’s ZETA-1 phase 2 trial of diabetic retinopathy candidate offers mixed results

January 26th 2023

Commercial real estate and your practice, part two with Colin Carr

UT Southwestern ophthalmologist shares techniques for cataract surgery complications

January 26th 2023

Tips, tricks, what to dos and what not to dos on how you can save money as a healthcare provider on your commercial real estate (Part 1)

ARVO announces recipients of 2023 Pfizer Ophthalmics Carl Camras Translational Research Award

January 26th 2023

Expanding gene therapy for Usher Syndrome Type 2A

January 25th 2023

Related Content

Ocuphire Pharma’s ZETA-1 phase 2 trial of diabetic retinopathy candidate offers mixed results

Commercial real estate and your practice, part two with Colin Carr

UT Southwestern ophthalmologist shares techniques for cataract surgery complications

Tips, tricks, what to dos and what not to dos on how you can save money as a healthcare provider on your commercial real estate (Part 1)

ARVO announces recipients of 2023 Pfizer Ophthalmics Carl Camras Translational Research Award

Expanding gene therapy for Usher Syndrome Type 2A

Terms and Conditions

Do Not Sell My Personal Information

Contact Info

2 Clarke Drive
Cranbury, NJ 08512

© 2023 MJH Life Sciences

All rights reserved.